Tarsus Pharmaceuticals, INC Form 4 insider transactions

William J. Link, a director at Tarsus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) in connection with his service as a non-employee director.

Chief Commercial Officer Aziz Mottiwala of Tarsus Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, reports the acquisition and disposal of company stock and Restricted Stock Units (RSUs) related to vesting and tax obligations.

Bobak Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, reports the acquisition of shares through RSU vesting and subsequent sale to cover tax obligations.

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, acquired stock options and restricted stock units on March 7, 2024.

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, received stock options for 42,500 shares and 28,702 restricted stock units (RSUs) on March 7, 2024.

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) on March 7, 2024, according to a Form 4 filing with the SEC.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs) on March 7, 2024.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Chief Operating Officer of Tarsus Pharmaceuticals, Neervannan Seshadri, reports the acquisition of stock options and restricted stock units.